Publications by authors named "Edgar Schuck"

Claim this Profile
A
A combined physiologically-based pharmacokinetic and quantitative systems pharmacology model for modeling amyloid aggregation in Alzheimer's disease.
Hugo Geerts, Mike Walker, Rachel Rose, Silke Bergeler, Piet H van der Graaf, Edgar Schuck

CPT Pharmacometrics Syst Pharmacol· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 1 Single Ascending and Multiple Ascending Dose Studies of Phosphodiesterase-9 Inhibitor E2027: Confirmation of Target Engagement and Selection of Phase 2 Dose in Dementia With Lewy Bodies Trial.
Ishani S Landry, Jagadeesh Aluri, Edgar Schuck, Mitsuhiro Ino, Kanta Horie

Alzheimer Dis Assoc Disord· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Physiologically-based pharmacokinetic modeling to predict drug interactions of lemborexant with CYP3A inhibitors.
Takashi Ueno, Yukiko Miyajima, Ishani Landry, Bojan Lalovic, Edgar Schuck

CPT Pharmacometrics Syst Pharmacol· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Drug-Drug Interaction Study of Benznidazole and E1224 in Healthy Male Volunteers.
Isabela Ribeiro, Bethania Blum, Jayme Fernandes, Glaucia Santina, Makoto Asada, Edgar Schuck

Antimicrob Agents Chemother· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Perampanel and pregnancy.
Blanca Vazquez, Torbjörn Tomson, Cindy Dobrinsky, Edgar Schuck, Terence J O'Brien

Epilepsia· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Changes in perampanel levels during de-induction: Simulations following carbamazepine discontinuation.
Edgar Schuck, Jim Ferry, Barry Gidal, Ziad Hussein

Acta Neurol Scand· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Quantitative Systems Pharmacology for Neuroscience Drug Discovery and Development: Current Status, Opportunities, and Challenges.
Hugo Geerts, John Wikswo, Piet H van der Graaf, Jane P F Bai, Chris Gaiteri, Edgar Schuck

CPT Pharmacometrics Syst Pharmacol· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Applications of Quantitative Systems Pharmacology in Model-Informed Drug Discovery: Perspective on Impact and Opportunities.
Erica L Bradshaw, Mary E Spilker, Richard Zang, Loveleena Bansal, Handan He, Edgar Schuck

CPT Pharmacometrics Syst Pharmacol· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Recommendations for the Design of Clinical Drug-Drug Interaction Studies With Itraconazole Using a Mechanistic Physiologically-Based Pharmacokinetic Model.
Yuan Chen, Tamara D Cabalu, Ernesto Callegari, Heidi Einolf, Lichuan Liu, Edgar Schuck

CPT Pharmacometrics Syst Pharmacol· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical Drug-Drug Interaction Potential of BFE1224, Prodrug of Antifungal Ravuconazole, Using Two Types of Cocktails in Healthy Subjects.
Yasuyuki Ishii, Yuko Ito, Shunji Matsuki, Kasumi Sanpei, Osamu Ogawa, Edgar L Schuck

Clin Transl Sci· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Physiologically Based Pharmacokinetic Model Qualification and Reporting Procedures for Regulatory Submissions: A Consortium Perspective.
Mohamad Shebley, Punam Sandhu, Arian Emami Riedmaier, Masoud Jamei, Rangaraj Narayanan, Edgar Schuck

Clin Pharmacol Ther· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetic/pharmacodynamic drug-drug interactions of avatrombopag when coadministered with dual or selective CYP2C9 and CYP3A interacting drugs.
Maiko Nomoto, Cynthia A Zamora, Edgar Schuck, Peter Boyd, Min-Kun Chang

Br J Clin Pharmacol· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical QSP Modeling in the Pharmaceutical Industry: An IQ Consortium Survey Examining the Current Landscape.
Marjoleen J M A Nijsen, Fan Wu, Loveleena Bansal, Erica Bradshaw-Pierce, Jason R Chan, Edgar Schuck

CPT Pharmacometrics Syst Pharmacol· March 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Translational pharmacokinetic-pharmacodynamic analysis in the pharmaceutical industry: an IQ Consortium PK-PD Discussion Group perspective.
Harvey Wong, Tonika Bohnert, Valeriu Damian-Iordache, Christopher Gibson, Cheng-Pang Hsu, Edgar Schuck

Drug Discov Today· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of enzyme inhibition on perampanel pharmacokinetics: Why study design matters.
Barry E Gidal, Rama Maganti, Antonio Laurenza, Haichen Yang, David A Verbel, Edgar Schuck

Epilepsy Res· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Eribulin shows high concentration and long retention in xenograft tumor tissues.
Michiko Sugawara, Krista Condon, Earvin Liang, Christopher DesJardins, Edgar Schuck

Cancer Chemother Pharmacol· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and pharmacokinetic profile of rufinamide in pediatric patients aged less than 4 years with Lennox-Gastaut syndrome: An interim analysis from a multicenter, randomized, active-controlled, open-label study.
Alexis Arzimanoglou, Jose A Ferreira, Andrew Satlin, Shannon Mendes, Betsy Williams, Edgar Schuck

Eur J Paediatr Neurol· May 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical pharmacokinetic/pharmacodynamic modeling and simulation in the pharmaceutical industry: an IQ consortium survey examining the current landscape.
Edgar Schuck, Tonika Bohnert, Arijit Chakravarty, Valeriu Damian-Iordache, Christopher Gibson, Virna Schuck

AAPS J· March 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel γ-secretase modulator, E2212, in healthy human subjects.
Yanke Yu, Veronika Logovinsky, Edgar Schuck, June Kaplow, Min-Kun Chang

J Clin Pharmacol· May 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design, synthesis, and pharmacological evaluation of fluorinated tetrahydrouridine derivatives as inhibitors of cytidine deaminase.
Dana Ferraris, Bridget Duvall, Greg Delahanty, Bipin Mistry, Jesse Alt, Edgar Schuck

J Med Chem· March 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A transcellular assay to assess the P-gp inhibition in early stage of drug development.
Jan-Shiang Taur, Edgar L Schuck, Nancy Y Wong

Drug Metab Lett· October 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characterization of the pharmacokinetics of a liposomal formulation of eribulin mesylate (E7389) in mice.
Yanke Yu, Christopher Desjardins, Phil Saxton, George Lai, Edgar Schuck

Int J Pharm· February 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, pharmacokinetics and pharmacodynamics of four-hour intravenous infusions of eritoran in healthy Japanese and Caucasian men.
Naoki Aikawa, Yoshio Okubo, Melvyn Lynn, Daniel P Rossignol, Y Nancy Wong, Edgar Schuck

Innate Immun· December 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetic characterization of a natural product-inspired novel MEK1 inhibitor E6201 in preclinical species.
Vipul Kumar, Edgar L Schuck, Robert D Pelletier, Nadia Farah, Krista B Condon

Cancer Chemother Pharmacol· January 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel second generation analogs of eribulin. Part II: Orally available and active against resistant tumors in vivo.
Sridhar Narayan, Eric M Carlson, Hongsheng Cheng, Krista Condon, Hong Du, Edgar Schuck

Bioorg Med Chem Lett· March 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis